Work

Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.8026

Authors: Corey Allan Carter, Arun Rajan, Eva Szabo, Sean Khozin, Anish Thomas, Christina E. Brzezniak, Udayan Guha, L. Austin Doyle, Corrine Keen, Seth M. Steinberg, Liqiang Xi, Mark Raffeld, Karen L. Reckamp, Stephen Koehler, Barbara Jennifer Gitlitz, Ravi Salgia, David R. Gandara, Everett E. Vokes, Giuseppe Giaccone

Institutions: Walter Reed National Military Medical Center, National Institutes of Health, National Cancer Institute, Center for Cancer Research, City Of Hope National Medical Center, City of Hope, USC Norris Comprehensive Cancer Center, University of Chicago, UC Davis Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2466381983

Cites:

Cited by: 20

Related to: 10